

Supplemental Disclosure for Change of Control Events

Nutri Pharmaceuticals Research, Inc.
5600 Tennyson Parkway, Suite 185; Plano, TX 75024

(888) 874-0852
info@resilienthc.org

The goal of this disclosure is to provide information with respect to a company's Change of Control event. Please address each of the below items to the best of the company's ability and to the extent they are applicable to the company's Change of Control event.

Disclosure of Change in Control and Other Material Events:

1. A description of event(s) and relevant date(s) resulting in the Change in Control.¹

On February 18, 2025, a reverse merger transaction was completed, and Resilient Healthcare Corp. became the controlling entity of Nutri Pharmaceuticals Research, Inc.

2. The name(s) of person(s) who acquired control and person(s) from whom control was assumed. For corporations or other business entities, please provide the name(s) of person(s) beneficially owning or controlling such corporations or entities.²

Acquirer: Resilient Healthcare Corp

Prior Controlling Entity: Existing shareholders of Nutri Pharmaceuticals Research, Inc.

Resilient Healthcare Corp now beneficially owns and controls the company post-merger.

3. The name(s) of person(s) that participated in, assisted in, organized, or brokered the transaction between the purchaser and seller, resulting in the Change in Control (if applicable).

Legal counsel for the transaction: Troutman Pepper Hamilton Sanders LLP

¹ A "Change in Control" shall mean any events resulting in:

- i. Any "person" (as such term is used in Sections 13(d) and 14(d) of the Exchange Act) becoming the "beneficial owner" (as defined in Rule 13d-3 of the Exchange Act), directly or indirectly, of securities of the Company representing fifty percent (50%) or more of the total voting power represented by the Company's then outstanding voting securities;
- ii. The consummation of the sale or disposition by the Company of all or substantially all of the Company's assets;
- iii. A change in the composition of the Board occurring within a two (2)-year period, as a result of which fewer than a majority of the directors are directors immediately prior to such change; or
- iv. The consummation of a merger or consolidation of the Company with any other corporation, other than a merger or consolidation which would result in the voting securities of the Company outstanding immediately prior thereto continuing to represent (either by remaining outstanding or by being converted into voting securities of the surviving entity or its parent) at least fifty percent (50%) of the total voting power represented by the voting securities of the Company or such surviving entity or its parent outstanding immediately after such merger or consolidation.

² See, Securities Exchange Act Rule 13d-3 for determination of "beneficial owner."

4. A description of assets acquired or disposed of in connection with the Change in Control and the names of the purchaser and seller of such assets (if applicable).

Resilient Healthcare Corp assumed all assets and liabilities of Nutri Pharmaceuticals Research, Inc., in accordance with the terms of the reverse merger. No separate asset sale occurred.

5. Amount and form (e.g., cash, equity securities, promissory note) of consideration paid in connection with the Change in Control.

The consideration paid by Resilient Healthcare Corp was based on equity securities, as outlined in the executed Merger Agreement. No cash or promissory notes were exchanged as standalone consideration.

6. A description of any material agreements or other events related to the Change in Control.

Nutri Pharmaceuticals Research, Inc. redomiciled from Nevada to Delaware and adopted Resilient Healthcare Corp's governance and operational structure as part of the transaction. The merger agreement and related corporate actions are available upon request or as filed with regulatory agencies, where applicable.

Certification:

Date: 05/28/2025

Signature: /s/ Marc Andiel

Officer Name: Marc Andiel